Benitec Biopharma Ltd Stock Buy Hold or Sell Recommendation
| BNTC Stock | USD 10.15 0.34 3.24% |
Given the investment horizon of 90 days and your slightly conservative level of risk, our recommendation regarding Benitec Biopharma Ltd is 'Strong Sell'. Macroaxis provides Benitec Biopharma buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding BNTC positions.
Check out Benitec Biopharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Benitec and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Benitec Biopharma Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Benitec |
Execute Benitec Biopharma Buy or Sell Advice
The Benitec recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Benitec Biopharma Ltd. Macroaxis does not own or have any residual interests in Benitec Biopharma Ltd or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Benitec Biopharma's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | About Average | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Benitec Biopharma Trading Alerts and Improvement Suggestions
| Benitec Biopharma had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 216 K. Net Loss for the year was (21.75 M) with profit before overhead, payroll, taxes, and interest of 75 K. | |
| Benitec Biopharma Ltd currently holds about 4.06 M in cash with (19.4 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.5. | |
| Benitec Biopharma has a poor financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Acquisition by Suvretta Capital Management, Llc of 3076 shares of Benitec Biopharma at 10.22 subject to Rule 16b-3 |
Benitec Biopharma Returns Distribution Density
The distribution of Benitec Biopharma's historical returns is an attempt to chart the uncertainty of Benitec Biopharma's future price movements. The chart of the probability distribution of Benitec Biopharma daily returns describes the distribution of returns around its average expected value. We use Benitec Biopharma Ltd price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Benitec Biopharma returns is essential to provide solid investment advice for Benitec Biopharma.
| Mean Return | 0.28 | Value At Risk | -4.52 | Potential Upside | 7.89 | Standard Deviation | 4.68 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Benitec Biopharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Benitec Stock Institutional Investors
| Shares | Lion Point Capital, Lp | 2024-09-30 | 39 K | Longwood Capital Partners Llc | 2024-09-30 | 29.8 K | Blackrock Inc | 2024-06-30 | 28 K | Northern Trust Corp | 2024-09-30 | 24.8 K | Citadel Advisors Llc | 2024-09-30 | 14.2 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 11.2 K | Gamma Investing Llc | 2024-09-30 | 6.5 K | Ubs Group Ag | 2024-06-30 | 2 K | Tower Research Capital Llc | 2024-06-30 | 891 | Suvretta Capital Management, Llc | 2024-06-30 | 1.7 M | Hhg Plc | 2024-06-30 | 900.8 K |
Benitec Biopharma Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (5.9M) | 10.0M | (15.7M) | (1.6M) | 48.4M | 50.9M | |
| Free Cash Flow | (7.6M) | (13.1M) | (15.9M) | (18.0M) | (19.6M) | (18.6M) | |
| Other Non Cash Items | 2K | (16K) | 10K | 717K | 1K | 950.0 | |
| Capital Expenditures | 95K | 221K | 13K | 1K | 179K | 150.1K | |
| Net Income | (8.3M) | (13.9M) | (18.2M) | (19.6M) | (21.8M) | (20.7M) | |
| End Period Cash Flow | 9.8M | 19.8M | 4.1M | 2.5M | 50.9M | 53.5M | |
| Depreciation | 374K | 424K | 392K | 381K | 343K | 253.0K | |
| Change To Netincome | 239K | 618K | 880K | 455K | 409.5K | 591.5K | |
| Change To Inventory | (700K) | (83K) | (1.1M) | (1.3M) | (1.2M) | (1.1M) | |
| Investments | (94K) | (221K) | (13K) | (1K) | (179K) | (188.0K) |
Benitec Biopharma Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Benitec Biopharma or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Benitec Biopharma's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Benitec stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.25 | |
β | Beta against Dow Jones | 0.17 | |
σ | Overall volatility | 4.76 | |
Ir | Information ratio | 0.03 |
Benitec Biopharma Volatility Alert
Benitec Biopharma Ltd shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Benitec Biopharma's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Benitec Biopharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Benitec Biopharma Fundamentals Vs Peers
Comparing Benitec Biopharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Benitec Biopharma's direct or indirect competition across all of the common fundamentals between Benitec Biopharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Benitec Biopharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Benitec Biopharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Benitec Biopharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Benitec Biopharma to competition |
| Fundamentals | Benitec Biopharma | Peer Average |
| Return On Equity | -0.92 | -0.31 |
| Return On Asset | -0.5 | -0.14 |
| Current Valuation | 168.02 M | 16.62 B |
| Shares Outstanding | 19.82 M | 571.82 M |
| Shares Owned By Insiders | 4.38 % | 10.09 % |
| Shares Owned By Institutions | 46.12 % | 39.21 % |
| Number Of Shares Shorted | 56.89 K | 4.71 M |
| Price To Earning | (5.10) X | 28.72 X |
| Price To Book | 3.67 X | 9.51 X |
| Price To Sales | 2,770 X | 11.42 X |
| Revenue | 216 K | 9.43 B |
| Gross Profit | 75 K | 27.38 B |
| EBITDA | (22.49 M) | 3.9 B |
| Net Income | (21.75 M) | 570.98 M |
| Cash And Equivalents | 4.06 M | 2.7 B |
| Cash Per Share | 0.50 X | 5.01 X |
| Total Debt | 284 K | 5.32 B |
| Debt To Equity | 0.28 % | 48.70 % |
| Current Ratio | 1.90 X | 2.16 X |
| Book Value Per Share | 4.68 X | 1.93 K |
| Cash Flow From Operations | (19.4 M) | 971.22 M |
| Short Ratio | 1.35 X | 4.00 X |
| Earnings Per Share | (5.51) X | 3.12 X |
| Target Price | 24.0 | |
| Number Of Employees | 16 | 18.84 K |
| Beta | 0.88 | -0.15 |
| Market Capitalization | 215.39 M | 19.03 B |
| Total Asset | 52.21 M | 29.47 B |
| Retained Earnings | (190.26 M) | 9.33 B |
| Working Capital | 46.75 M | 1.48 B |
| Current Asset | 19.38 M | 9.34 B |
| Current Liabilities | 1.03 M | 7.9 B |
| Net Asset | 52.21 M |
Note: Acquisition by Suvretta Capital Management, Llc of 3076 shares of Benitec Biopharma at 10.22 subject to Rule 16b-3 [view details]
Benitec Biopharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Benitec . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Benitec Biopharma Buy or Sell Advice
When is the right time to buy or sell Benitec Biopharma Ltd? Buying financial instruments such as Benitec Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Benitec Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Large Growth Funds Thematic Idea Now
Large Growth Funds
Funds or Etfs that invest in stocks of large-sized companies with above-average risk and growth rate. The Large Growth Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Large Growth Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Benitec Biopharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Benitec Biopharma. If investors know Benitec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Benitec Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.51) | Revenue Per Share 0.003 | Quarterly Revenue Growth 0.125 | Return On Assets (0.50) | Return On Equity (0.92) |
The market value of Benitec Biopharma is measured differently than its book value, which is the value of Benitec that is recorded on the company's balance sheet. Investors also form their own opinion of Benitec Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Benitec Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Benitec Biopharma's market value can be influenced by many factors that don't directly affect Benitec Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Benitec Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Benitec Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Benitec Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.